EA200200611A1 - Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции - Google Patents

Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции

Info

Publication number
EA200200611A1
EA200200611A1 EA200200611A EA200200611A EA200200611A1 EA 200200611 A1 EA200200611 A1 EA 200200611A1 EA 200200611 A EA200200611 A EA 200200611A EA 200200611 A EA200200611 A EA 200200611A EA 200200611 A1 EA200200611 A1 EA 200200611A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
tetrahydropyridines
new
production
independently represent
Prior art date
Application number
EA200200611A
Other languages
English (en)
Other versions
EA004858B1 (ru
Inventor
Марко Барони
Бернар Бурри
Розанна Кардамоне
Пьер Казелла
Original Assignee
Санофи-Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Синтелябо filed Critical Санофи-Синтелябо
Publication of EA200200611A1 publication Critical patent/EA200200611A1/ru
Publication of EA004858B1 publication Critical patent/EA004858B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Настоящее изобретение относится к соединениям формулы (I)где Rпредставляет собой атом водорода или галогена либо группу CF; Rи Rнезависимо представляют собой атом водорода или метильную группу; n и n', каждый независимо, представляют собой 0 или 1; * представляет собой положения связи; А представляет собой N или СН; Х представляет собой атом серы или кислорода; Rи Rнезависимо представляют собой атом водорода или (C-C)алкильную группу; а также к их солям или сольватам. Настоящее изобретение также относится к способу получения указанных соединений и к содержащим их фармацевтическим композициям.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200611A 2000-01-06 2000-12-29 Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции EA004858B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0000113A FR2803593B1 (fr) 2000-01-06 2000-01-06 Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
PCT/FR2000/003741 WO2001049684A1 (fr) 2000-01-06 2000-12-29 Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
EA200200611A1 true EA200200611A1 (ru) 2002-12-26
EA004858B1 EA004858B1 (ru) 2004-08-26

Family

ID=8845654

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200611A EA004858B1 (ru) 2000-01-06 2000-12-29 Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции

Country Status (28)

Country Link
US (1) US6689797B2 (ru)
EP (1) EP1248785B1 (ru)
JP (1) JP2004501861A (ru)
KR (1) KR100755103B1 (ru)
CN (1) CN1200939C (ru)
AT (1) ATE297918T1 (ru)
AU (1) AU782650B2 (ru)
BR (1) BR0016921A (ru)
CA (1) CA2395969C (ru)
CZ (1) CZ300658B6 (ru)
DE (1) DE60020885T2 (ru)
EA (1) EA004858B1 (ru)
EE (1) EE04814B1 (ru)
FR (1) FR2803593B1 (ru)
HK (1) HK1050532A1 (ru)
HU (1) HU224815B1 (ru)
IL (1) IL150605A0 (ru)
IS (1) IS2472B (ru)
ME (1) MEP21808A (ru)
MX (1) MXPA02006709A (ru)
NO (1) NO322598B1 (ru)
NZ (1) NZ519723A (ru)
PL (1) PL202761B1 (ru)
RS (1) RS50432B (ru)
SK (1) SK285557B6 (ru)
UA (1) UA72017C2 (ru)
WO (1) WO2001049684A1 (ru)
ZA (1) ZA200205223B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271554T1 (de) * 1999-10-22 2004-08-15 Sanofi Synthelabo Phenyl- und pyridyl-tetrahydro-pyridine mit tnf inhibitorischer wirkung
FR2831166B1 (fr) * 2001-10-18 2004-02-27 Sanofi Synthelabo Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
DK2137162T3 (en) * 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
US11129746B2 (en) 2010-06-23 2021-09-28 Dental Choice Holdings Llc Method and oral appliance for improving air intake and reducing bruxism
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
CA3085388A1 (en) 2017-12-12 2019-06-20 Queen's University At Kingston Compounds and methods for inhibiting cyp26 enzymes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2060816C3 (de) * 1970-12-10 1980-09-04 Merck Patent Gmbh, 6100 Darmstadt 4-Phenylpiperidinderivate Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen enthaltend diese Verbindungen
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
GB9604036D0 (en) * 1996-02-26 1996-04-24 Merck Sharp & Dohme Therapeutic agents
FR2751645B1 (fr) * 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine

Also Published As

Publication number Publication date
RS50432B (sr) 2009-12-31
HU224815B1 (en) 2006-02-28
YU51302A (sh) 2005-06-10
ATE297918T1 (de) 2005-07-15
NO20023251D0 (no) 2002-07-04
CN1200939C (zh) 2005-05-11
IS2472B (is) 2008-12-15
NZ519723A (en) 2005-08-26
HUP0204394A2 (en) 2003-05-28
EP1248785A1 (fr) 2002-10-16
AU3031101A (en) 2001-07-16
PL357082A1 (en) 2004-07-12
PL202761B1 (pl) 2009-07-31
MXPA02006709A (es) 2002-10-23
ZA200205223B (en) 2004-01-26
CA2395969C (en) 2009-05-19
KR20020063291A (ko) 2002-08-01
SK285557B6 (sk) 2007-03-01
FR2803593A1 (fr) 2001-07-13
CA2395969A1 (en) 2002-07-03
MEP21808A (en) 2010-06-10
EA004858B1 (ru) 2004-08-26
CZ20022302A3 (cs) 2002-10-16
SK9622002A3 (en) 2003-03-04
WO2001049684A1 (fr) 2001-07-12
DE60020885T2 (de) 2006-05-11
EP1248785B1 (fr) 2005-06-15
JP2004501861A (ja) 2004-01-22
KR100755103B1 (ko) 2007-09-04
EE200200382A (et) 2003-12-15
IL150605A0 (en) 2003-02-12
CN1433412A (zh) 2003-07-30
US20030083347A1 (en) 2003-05-01
HK1050532A1 (en) 2003-06-27
AU782650B2 (en) 2005-08-18
EE04814B1 (et) 2007-04-16
BR0016921A (pt) 2002-10-15
CZ300658B6 (cs) 2009-07-08
NO322598B1 (no) 2006-10-30
IS6452A (is) 2002-06-28
HUP0204394A3 (en) 2005-04-28
DE60020885D1 (de) 2005-07-21
UA72017C2 (en) 2005-01-17
NO20023251L (no) 2002-09-06
FR2803593B1 (fr) 2002-02-15
US6689797B2 (en) 2004-02-10

Similar Documents

Publication Publication Date Title
EA200300428A1 (ru) Антагонисты метаботропных рецепторов глутамата
ID17851A (id) Persenyawaan heterosiklis, produksi dan pemakaiannya
EA200400111A1 (ru) 7-аминотриазолопиримидины, способ и промежуточные продукты для их получения, содержащие их средства, а также их применение для борьбы с фитопатогенными грибами
EA200600358A1 (ru) Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2
HRP20021023B1 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
HRP20070529T3 (en) Imidazole derivatives as glutmate receptor antagonists
EA200200611A1 (ru) Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
ID25477A (id) Turunan-turunan spiropiperidin
EA200200523A1 (ru) Новые разветвленные замещенные аминопроизводные 3-амино-1-фенил-1h[1,2,4]триазола, способы их получения и содержащие их фармацевтические композиции
EA200101209A1 (ru) Новые производные бензола, способ их получения и фармацевтические композиции, содержащие их
MXPA04003568A (es) Aralquil-tetrahidro-piridinas su preparacion y composiciones farmaceuticas que contienen las mismas.
EA200300458A1 (ru) Новые соединения аминотриазолона, способ их получения и фармацевтические композиции, содержащие их
JO2433B1 (en) Preparation of heterocyclic lindane landscapes
EA200500032A1 (ru) Производные ацилоксипирролидина и их применение в качестве лигандов v1b или v1b и v1a рецепторов
MY136065A (en) Prodrugs to nmda receptor ligands
EA200200665A1 (ru) Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие
EA200400469A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
KR920012100A (ko) 비스포스폰산 유도체, 이의 제조 및 용도
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
FR2826005B1 (fr) Synthese totale de la galanthamine, de ses analogues et de ses derives
ATE367377T1 (de) Bis(5-aryl-2-pyridyl)derivate
DE69011714T2 (de) Kalziumantagonisten.

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU